Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2026-06-30 @ 1:35 AM
Study NCT ID:
NCT04223856
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-13
First Post:
2020-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Urothelial Cancer | View |